Literature DB >> 21889777

Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.

D Figarella-Branger1, A Maues de Paula, C Colin, C Bouvier.   

Abstract

Adult gliomas are most often infiltrative. The World Health Organization (WHO) has classed them into three major groups according to the presomptive cell of origin: astrocytoma, oligodendroglioma and mixed oligoastrocytoma. Depending on the presence or absence of a small number of signs of anaplasia (mitosis, nuclear atypia, cell density, microvascular proliferation and necrosis) the WHO distinguishes grade II (LGG), III (anaplastic), and IV (glioblastomas, GBM). Mutation in the isocitrate deshydrogenase I and II (IDH1 and 2) genes distinguishes grade II, III and secondary GBM from primary GBM. Moreover two additional genetic alterations are recorded in grade II and III gliomas: TP53 mutations that characterize astrocytomas and 1p19q codeletion (as the result of t(1;19)(q10;p10) translocation) recorded in oligodendrogliomas. Mixed gliomas, the most non-reproducible category, share with astrocytomas and oligodendrogliomas the same genetic alterations. Interestingly TP53 mutation (p53+) and 1p19q codeletion (1p19q+) are mutually exclusive and involve IDH mutated (IDH+) glial precursor cells. According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Interestingly, p53 expression and internexin alpha (INA) expression can replace to some extent TP53 mutation and 1p19 codeletion, respectively. Moreover the antibody directed against the IDH1R132H isoform is highly specific. Because this mutation is the most frequent it is sufficient to assess IDH status in more than 80% of grade II and III gliomas. Taken together these three immunohistochemical markers are contribute greatly to the classification of gliomas and should be tested routinely as diagnostic markers. Finally, although GBM are genetically heterogeneous, the vast majority display EGFR amplification, often associated with EGFR expression, which can be helpful for diagnosis in certain cases.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889777     DOI: 10.1016/j.neurol.2011.07.006

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  10 in total

1.  A histopathological diagnostic marker for human spinal astrocytoma: expression of glial fibrillary acidic protein-δ.

Authors:  Dong Hwa Heo; Se Hoon Kim; Kyung-Moo Yang; Yong Jun Cho; Keung Nyun Kim; Do Heum Yoon; Tae-Cheon Kang
Journal:  J Neurooncol       Date:  2012-02-09       Impact factor: 4.130

Review 2.  IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.

Authors:  Davide Tiziano Di Carlo; Hugues Duffau; Federico Cagnazzo; Nicola Benedetto; Riccardo Morganti; Paolo Perrini
Journal:  Neurosurg Rev       Date:  2018-06-26       Impact factor: 3.042

3.  p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.

Authors:  Sabine Heublein; Sabina K Page; Doris Mayr; Nina Ditsch; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-02       Impact factor: 4.553

4.  Development and Validation of a Radiosensitivity Prediction Model for Lower Grade Glioma Based on Spike-and-Slab Lasso.

Authors:  Zixuan Du; Shang Cai; Derui Yan; Huijun Li; Xinyan Zhang; Wei Yang; Jianping Cao; Nengjun Yi; Zaixiang Tang
Journal:  Front Oncol       Date:  2021-07-30       Impact factor: 6.244

5.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Authors:  Yuchen Jiao; Patrick J Killela; Zachary J Reitman; Ahmed B Rasheed; Christopher M Heaphy; Roeland F de Wilde; Fausto J Rodriguez; Sergio Rosemberg; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Chetan Bettegowda; Nishant Agrawal; Eric Lipp; Christopher Pirozzi; Giselle Lopez; Yiping He; Henry Friedman; Allan H Friedman; Gregory J Riggins; Matthias Holdhoff; Peter Burger; Roger McLendon; Darell D Bigner; Bert Vogelstein; Alan K Meeker; Kenneth W Kinzler; Nickolas Papadopoulos; Luis A Diaz; Hai Yan
Journal:  Oncotarget       Date:  2012-07

6.  Integrins and p53 pathways in glioblastoma resistance to temozolomide.

Authors:  Sophie Martin; Hana Janouskova; Monique Dontenwill
Journal:  Front Oncol       Date:  2012-10-31       Impact factor: 6.244

7.  Sublethal dose of irradiation enhances invasion of malignant glioma cells through p53-MMP 2 pathway in U87MG mouse brain tumor model.

Authors:  Jian Pei; In-Ho Park; Hyang-Hwa Ryu; Song-Yuan Li; Chun-Hao Li; Sa-Hoe Lim; Min Wen; Woo-Youl Jang; Shin Jung
Journal:  Radiat Oncol       Date:  2015-08-06       Impact factor: 3.481

8.  KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

Authors:  Sabine Heublein; Katinka Grasse; Harald Hessel; Alexander Burges; Miriam Lenhard; Jutta Engel; Thomas Kirchner; Udo Jeschke; Doris Mayr
Journal:  BMC Cancer       Date:  2013-10-18       Impact factor: 4.430

9.  Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma.

Authors:  Guangrong Lu; Jeffrey T Chang; Zheyu Liu; Yong Chen; Min Li; Jay-Jiguang Zhu
Journal:  Mol Neurobiol       Date:  2015-11-28       Impact factor: 5.590

10.  Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.

Authors:  Yulong Lan; Jiacheng Lou; Jiliang Hu; Zhikuan Yu; Wen Lyu; Bo Zhang
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.